26.8 C
New York
Thursday, July 3, 2025

Tag: pharmaceutical

Fangzhou Tops China’s App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in...

Water-based Barrier Coatings Market worth $1.85 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- The report 'Water-based Barrier Coatings Market by Component (Water, Filler, Binder, Additives), Barrier Type (Water Vapor,...

Water-based Barrier Coatings Market worth $1.85 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- The report 'Water-based Barrier Coatings Market by Component (Water, Filler, Binder, Additives), Barrier Type (Water Vapor,...

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

Gwo Xi Stem Cell Company Powers Local Regenerative Medicine, Partners with Japan to Open a New Era

HSINCHU, July 3, 2025 /PRNewswire/ -- Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in...

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...

WST DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025

LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025.

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

TORONTO, July 2, 2025 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept),...

2 Day Pharmaceutical, Biopharmaceutical, Biologics and Medical Device FDA Inspection Preparedness and Compliance Seminar (ONLINE EVENT: September 3-4, 2025)

Join our two-day seminar designed for pharmaceutical, biopharmaceutical, biologics, and medical device professionals to master FDA inspections. Gain hands-on strategies to efficiently prepare, conduct, and respond. Includes slides, certificates, Q&A, and inspection handouts. Optimize outcomes.
Join our two-day seminar designed for pharmaceutical, biopharmaceutical, biologics, and medical device professionals to master FDA inspections. Gain hands-on strategies to efficiently prepare, conduct, and respond. Includes slides, certificates, Q&A, and inspection handouts. Optimize outcomes.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical